A Brief Review of Zuranolone

Authors

Aubrey A. Jackson, Department of Psychiatry, Phoenixville Hospital-Tower Health, Phoenixville, PAFollow

Abstract

Zuranolone, a novel analog of allopregnanolone, has been approved by the U.S. Food and Drug Administration (FDA) as the first oral medication approved for the treatment of postpartum depression in adults. Developed by Sage Therapeutics under the brand name Zurzuvae, zuranolone was approved by the FDA on August 4^th, 2023.¹ Zuranolone is a modified version of brexanolone (sold under the brand name Zulpresso), an intravenously administered allopregnanolone formulation that was previously the only FDA-approved medication for postpartum depression. Zuranolone offers a more accessible treatment option for patients with efficacy established in clinical trials. Its approval expands the treatment landscape for depression, especially in the peripartum period, and marks a crucial step forward in psychopharmacological innovation.

Recommended Citation

Jackson AA. A Brief Review of Zuranolone. Transformative Medicine. 2024; 3(3):75-77. doi: https://doi.org/10.54299/tmed/lnab4981.